Home › Employers › Cycle Pharmaceuticals Inc.
Cycle Pharmaceuticals Inc.: H-1B salaries and sponsorship
Cycle Pharmaceuticals Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $125,000.
Does Cycle Pharmaceuticals Inc. sponsor H-1B visas?
Cycle Pharmaceuticals Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Feb 12, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Director, Market Access & Distribution | 2 | $130,000 |
| Manager, Market Access & Distribution | 1 | $90,230 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 2 | $112,615 |
| FY2025 | 1 | $125,000 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Director, Market Access & Distribution | $125,000–$180,000 E-3 · Level II | Boston, MA | Feb 12, 2025 | Mar 31, 2025 | Certified |
| Director, Market Access & Distribution | $135,000–$165,000 E-3 · Level IV | Boston, MA | May 26, 2023 | Jun 1, 2023 | Certified |
| Manager, Market Access & Distribution | $90,230–$120,000 E-3 · Level II | Boston, MA | Jan 12, 2023 | Apr 24, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).